Edition:
India

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

16.40USD
2:29am IST
Change (% chg)

$-0.10 (-0.61%)
Prev Close
$16.50
Open
$16.75
Day's High
$17.15
Day's Low
$16.15
Volume
290,287
Avg. Vol
359,310
52-wk High
$18.40
52-wk Low
$2.85

Latest Key Developments (Source: Significant Developments)

Sangamo Says European Medicines Agency Recommends Orphan Medicinal Product Designation For Investigational Genome Editing Treatments
Friday, 8 Dec 2017 

Dec 7 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO ANNOUNCES EUROPEAN MEDICINES AGENCY RECOMMENDATION OF ORPHAN MEDICINAL PRODUCT DESIGNATION FOR INVESTIGATIONAL GENOME EDITING TREATMENTS FOR MPS I AND MPS II.SANGAMO THERAPEUTICS - PHASE 1/2 CLINICAL TRIALS FOR PROGRAMS, EVALUATING SB-318 & SB-913 IN ADULTS WITH MPS I AND MPS II, ARE ENROLLING SUBJECTS.  Full Article

Sangamo says patient received therapy intended to precisely edit DNA of cells directly inside body​
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Sangamo Therapeutics Inc -:Sangamo announces treatment of first patient in landmark phase 1/2 clinical trial evaluating in vivo genome editing for MPS II.‍A patient has received a therapy intended to precisely edit DNA of cells directly inside body​.  Full Article

Sangamo Therapeutics posts Q3 loss per share $0.15
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Sangamo Therapeutics Inc :Sangamo Therapeutics reports third quarter 2017 financial results.Q3 revenue $11.8 million versus I/B/E/S view $10.4 million.Q3 loss per share $0.15.Sees FY 2017 revenue $30 million to $40 million.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Sangamo Therapeutics Inc - ‍company expects that revenues will be in range of $30 million to $40 million in 2017​.FY2017 revenue view $33.2 million -- Thomson Reuters I/B/E/S.  Full Article

Sangamo Biosciences receives orphan drug designation from the FDA for sb-fix, the first application of therapeutic in vivo genome editing
Tuesday, 6 Sep 2016 

Sangamo Biosciences Inc : Fix, the first application of therapeutic in vivo genome editing .Sangamo Biosciences Inc Says Expects To Initiate A Phase 1/2 Clinical Study (Sb fix-1501) in adult subjects with disease in 2016.  Full Article

Sangamo Bio sees FY 2016 revenue $12 million to $17 million
Thursday, 4 Aug 2016 

Sangamo Biosciences Inc : Sangamo biosciences reports second quarter 2016 financial results . Q2 revenue view $5.4 million -- Thomson Reuters I/B/E/S . Sees fy 2016 revenue $12 million to $17 million . Q2 revenue $3.7 million versus $8.4 million . Q2 loss per share $0.38 . Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S .Sangamo expects that operating expenses will be in range of $85 million to $95 million for 2016.  Full Article

Sangamo BioSciences announces FDA clearance
Monday, 20 Jun 2016 

Sangamo BioSciences Inc : To initiate SB-913-1602 clinical study for MPS II in second half of 2016 .Announces FDA clearance of investigational new drug application for ZFN-mediated genome editing treatment of MPS II.  Full Article

Sangamo Biosciences says CEO Edward Lanphier to retire
Wednesday, 1 Jun 2016 

Sangamo Biosciences Inc : Sangamo Biosciences announces retirement of Edward Lanphier as president and CEO; Sandy Macrae named as successor . Current chairman William Ringo to remain on board .Lanphier to assume chairmanship of board of directors.  Full Article

Sangamo BioSciences Inc reaffirms FY 2016 revenue guidance
Tuesday, 3 May 2016 

Sangamo BioSciences Inc:Expects that revenues will be in the range of $20 million to $25 million in FY 2016, inclusive of research funding from existing collaborations.  Full Article

BRIEF-Sangamo Therapeutics posts Q3 loss per share $0.15

* Sangamo Therapeutics reports third quarter 2017 financial results